Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Papp, K. [1 ]
Reich, K. [2 ]
Blauvelt, A. [3 ]
Baran, W. [4 ]
Bolduc, C. [5 ,6 ]
Toth, D. [7 ,8 ]
Gottlieb, A. B. [9 ]
Thaci, D. [10 ]
Li, J. [11 ]
Nirula, A. [11 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Wroclaw Med Univ, Wroclaw, Poland
[5] Univ Montreal, Montreal, PQ, Canada
[6] Innovaderm Res, Montreal, PQ, Canada
[7] XLR8 Med Res, Windsor, ON, Canada
[8] Prob Med Res, Windsor, ON, Canada
[9] Tufts Med Ctr, Boston, MA USA
[10] Med Univ Lubeck, D-23538 Lubeck, Germany
[11] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
043
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [32] Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study
    Dogra, Sunil
    Krupashankar
    Budamakuntla, Leelavathy
    Srinivas, C. R.
    Khopkar, Uday
    Gupta, Sandesh
    Shetty, Narendra
    Pratap, Dasiga Venkata Subrahmanya
    Gopal, M. G.
    Rao, T. Narayana
    Garg, Vijay
    Sumathy, T. K.
    Saraswat, Abir
    Bhat, Ramesh
    Kura, Mahendra
    Pandey, Neeraj
    Shah, Radha
    Krishna, Kotla Sai
    Padmaja, Dalavai
    Manmohan, G.
    Ramakrishnan, M. S.
    Barve, Abhijit
    Montero, Enrique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 331 - 333
  • [33] Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial
    Yang Hai-zhen
    Wang Ke
    Jin Hong-zhong
    Gao Tian-wen
    Xiao Sheng-xiang
    Xu Jin-hua
    Wang Bao-xi
    Zhang Fu-ren
    Li Chun-yang
    Liu Xiao-ming
    Tu Cai-xia
    Ji Su-zhen
    Shen Yang
    Zhu Xue-jun
    CHINESE MEDICAL JOURNAL, 2012, 125 (11) : 1845 - 1851
  • [34] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    Amy McMichael
    Seemal R. Desai
    Aamir Qureshi
    Shipra Rastogi
    Andrew F. Alexis
    American Journal of Clinical Dermatology, 2019, 20 : 267 - 276
  • [35] Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
    Sofen, Howard L.
    Gebauer, Kurt
    Spelman, Lynda
    Yamauchi, Paul S.
    Yao, Siu-Long
    Nishandar, Tushar
    Kopeloff, Iris
    Crane, Michael
    Gogineni, Ranga
    Kothekar, Mudgal
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (04) : 816 - 824
  • [36] A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis
    Forman, S.
    Pariser, D. M.
    Poulin, Y.
    Vincent, M. S.
    Gilbert, S. A.
    Kieras, E. M.
    Qiu, R.
    Yu, D.
    Papacharalambous, J.
    Peeva, E.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 37 - 37
  • [37] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    McMichael, Amy
    Desai, Seemal R.
    Qureshi, Aamir
    Rastogi, Shipra
    Alexis, Andrew F.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 267 - 276
  • [38] Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-MorbiditiesSubanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Alexa B. Kimball
    Arielle G. Bensimon
    Annie Guerin
    Andrew P. Yu
    Eric Q. Wu
    Martin M. Okun
    Yanjun Bao
    Shiraz R. Gupta
    Parvez M. Mulani
    American Journal of Clinical Dermatology, 2011, 12 : 51 - 62
  • [39] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis
    Guntupalli, Kalpalatha
    Dean, Nathan
    Morris, Peter E.
    Bandi, Venkata
    Margolis, Benjamin
    Rivers, Emanuel
    Levy, Mitchell
    Lodato, Robert F.
    Ismail, Preeti M.
    Reese, Amber
    Schaumberg, John P.
    Malik, Rajesh
    Dellinger, R. Phillip
    CRITICAL CARE MEDICINE, 2013, 41 (03) : 706 - 716
  • [40] Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study
    Krupashankar, D. S.
    Dogra, Sunil
    Kura, Mahendra
    Saraswat, Abir
    Budamakuntla, Leelavathy
    Sumathy, T. K.
    Shah, Radha
    Gopal, M. G.
    Rao, T. Narayana
    Srinivas, C. R.
    Bhat, Ramesh
    Shetty, Narendra
    Manmohan, G.
    Krishna, Kotla Sai
    Padmaja, Dalavoi
    Pratap, Dasiga Venkata Subrahmanya
    Garg, Vijay
    Gupta, Sandesh
    Pandey, Neeraj
    Khopkar, Uday
    Montero, Enrique
    Ramakrishnan, M. S.
    Nair, Pradip
    Ganapathi, Prasanna C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (03) : 484 - 492
12345